Three aromatase inhibitors (letrozole, anastrozole, and exemestane) are currently approved by the FDA and used in the clinic to treat early locally advanced and metastatic ER+ breast cancer [49]. This evidence concerns the gene CYP19A1 and breast carcinoma.